Hayes Mairead, Curley Gerard F, Masterson Claire, Devaney James, O'Toole Daniel, Laffey John G
Regenerative Medicine Institute, National University of Ireland, Galway, Ireland.
Anaesthesia, School of Medicine, Clinical Sciences Institute, National University of Ireland, Galway, Ireland.
Intensive Care Med Exp. 2015 Dec;3(1):29. doi: 10.1186/s40635-015-0065-y. Epub 2015 Oct 15.
The potential for mesenchymal stem cells (MSCs) to reduce the severity of experimental lung injury has been established in several pre-clinical studies. We have recently demonstrated that MSCs, and MSC-secreted factors (secretome), enhance lung repair and regeneration at 48 h following ventilation-induced lung injury (VILI). We wished to determine the potential for MSC therapy to exert beneficial effects in the early recovery phase following VILI when ongoing injury coexists with processes of repair, and to compare the efficacy of MSC therapy to the use of the secretome alone.
Male Sprague-Dawley rats were anesthetized, oro-tracheally intubated, and subjected to high stretch mechanical ventilation until lung compliance had declined by 50 % of baseline. Animals were then weaned from mechanical ventilation, and anesthesia discontinued. Once awake and spontaneously ventilating, animals received an intravenous injection of either rodent MSCs (10 million/kg), MSC-conditioned medium, fibroblasts (10 million/kg), or vehicle. Thereafter, the animals were allowed to recover and the extent of lung injury/repair was determined after 4 h.
Treatment with MSCs diminished injury and enhanced recovery following VILI to a greater extent compared to MSC-conditioned medium, with fibroblasts proving ineffective. MSCs, but not their conditioned medium, attenuated indices of lung injury including oxygenation, respiratory compliance, and lung edema. Total lung water as assessed by wet:dry ratio, bronchoalveolar lavage total inflammatory cell, neutrophil counts, and alveolar IL-6 concentrations were reduced in the animals that received MSC therapy.
The immunomodulating and/or reparative effect of MSCs is evident early after VILI in this model. MSC-conditioned medium was not as effective as the cells themselves in diminishing injury and restoring lung structure and function.
多项临床前研究已证实间充质干细胞(MSC)有减轻实验性肺损伤严重程度的潜力。我们最近证明,在通气诱导的肺损伤(VILI)后48小时,MSC及其分泌因子(分泌组)可促进肺修复和再生。我们希望确定MSC疗法在VILI后的早期恢复阶段(此时持续性损伤与修复过程并存)发挥有益作用的潜力,并比较MSC疗法与单独使用分泌组的疗效。
将雄性Sprague-Dawley大鼠麻醉,经口气管插管,进行高张力机械通气,直至肺顺应性下降至基线的50%。然后使动物脱离机械通气,并停止麻醉。动物清醒并自主通气后,静脉注射啮齿类MSC(1000万/kg)、MSC条件培养基、成纤维细胞(1000万/kg)或赋形剂。此后,让动物恢复,并在4小时后确定肺损伤/修复的程度。
与MSC条件培养基相比,MSC治疗在VILI后能更显著地减轻损伤并促进恢复,而成纤维细胞证明无效。MSC而非其条件培养基可减轻包括氧合、呼吸顺应性和肺水肿在内的肺损伤指标。接受MSC治疗的动物的肺湿干比、支气管肺泡灌洗总炎症细胞、中性粒细胞计数和肺泡IL-6浓度所评估的肺总含水量降低。
在该模型中,VILI后早期即可明显看出MSC的免疫调节和/或修复作用。MSC条件培养基在减轻损伤以及恢复肺结构和功能方面不如细胞本身有效。